SFEBES2021 Poster Presentations Reproductive Endocrinology (31 abstracts)
Impact of pharmacological Interventions on androgen hormones in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials
Mohammed Abdalla 1 , Najeeb Shah 1 , Harshal Deshmukh 1 , Amirhossein Sahebkar 2,3 , Linda Östlundh 4 , Rami H Al-Rifai 5 , Stephen L Atkin 6 & Thozhukat Sathyapalan 1
1Academic Diabetes, Endocrinology and Metabolism. University of Hull, Hull York Medical School (HYMS), Hull, United Kingdom; 2Biotechnology Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 3Applied Biomedical Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 4College of Medicine and Health Sciences, The National Medical Library, United Arab Emirates University, Al Ain, UAE; 5College of Medicine and Health Sciences, Institute of Public Health, United Arab Emirates University, Al Ain, UAE; 6School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Adliya, Bahrain
Context: Polycystic ovary syndrome (PCOS) is a complex endocrine disease that affects women of reproductive age and characterised by biochemical and clinical androgen excess.
Aim: To review the available literature on the effectiveness of the various pharmacological interventions on androgen hormones in women with PCOS.
Data source: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane library and the Web of Science in April 2020 and updated the search in March 2021.
Data synthesis: Two reviewers selected eligible studies and extracted data, and the review is reported according to the 2020 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).
Results: of 814 randomised clinical trials (RCTs) located in the search, 92 met the eligibility criteria. There were significant reductions in total testosterone with metformin vs placebo (SMD:-0.33; 95% CI-0.49 to-0.17, P < 0.0001, moderate grade evidence) and dexamethasone vs placebo (MD:-0.86 nmol/l ; 95% CI:-1.34 to-0.39, P = 0.0004, very low-grade evidence). Significant reductions in the free testosterone with sitagliptin vs placebo (SMD: -0.47; 95% CI: -0.97 to 0.04, P = 0.07, very low-grade evidence), in dehydroepiandrosterone sulphate (DHEAS) with flutamide vs finasteride (MD: -0.37 µg/dL; 95% CI: -0.05 to -0.58, P = 0.02, very low-grade evidence), in luteinising hormone (LH) with simvastatin +OCP vs OCP (MD: -2.02 IU/l; 95% CI: -3.52 to -0.52, p = 0.008, very low-grade evidence), in follicular stimulating hormone (FSH) with rosiglitazone vs placebo (MD:-0.32; 95% CI: -0.61 to -0.02, P = 0.04, very low-grade evidence) and a significant increase in sex hormone-binding globulin (SHBG) with oral contraceptive pill (OCP) (35 µg EE/2 mg CPA) vs placebo (MD: 103.30 nmol/l ; 95% CI: 55.54 to 151.05,P < 0.0001, very low-grade evidence) were observed.
Conclusion: metformin, dexamethasone, flutamide, OCP, and rosiglitazone have significantly reduced androgen hormones in women with PCOS.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more